Congestive in Biological Technology
Navigation Links
Congestive in Biological Technology
... cardiac toxicity. Myocardial damage may lead to congestive heart failure and may occur as the total ... should be carefully monitored
congestive heart failure or cardiomyopathy may occur after ... events (including myocardial infarction, stroke, congestive heart failure, and hemodialysis vascular access ...
... intended to prevent or reverse the progression of congestive heart failure in patients who have an enlarged ... heart mitral valve which contributed to congestive heart failure. During the surgery to repair the ... of the left ventricle, which is typical in congestive heart failure. As such, this new therapy has the ...
... evaluating ubiquinol's effects on late-stage congestive heart failure showed that the newly available ... "In 25 years of experience in treating congestive heart failure, we have consistently seen the best ... levels in these seven patients with end-stage congestive heart failure was associated with overall ...
... use in treatment of acute systemic hypertension, congestive heart failure and hemorrhagic shock. The ... the next fiscal year for treatment of acute congestive heart failure; -- Advancing new Palatin ... use in treatment of acute systemic hypertension, congestive heart failure and other diseases. Palatin's ...
... development for treatment of acute decompensated congestive heart failure (CHF). The Phase I trial was ... the subcutaneous route of administration. About congestive Heart Failure (CHF) Currently in the U.S., CHF ... over 1,100,000 hospitalizations for CHF in 2004. congestive heart failure has tremendous human and financial ...
... I clinical trial for MyoCell SDF-1 (Stromal Derived Factor - 1) to treat congestive heart failure. The REGEN trial will enroll 15 patients in a multicenter, ... safety and cardiovascular effects of the implantation of MyoCell SDF-1 in congestive heart failure patients post myocardial infarction(s). MyoCell SDF-1 ...
... vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and ... (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of ...
... of doxorubicin, a dose at which 5.6% of patients are expected to develop congestive heart failure (CHF). At cumulative doses of doxorubicin in excess of ... (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of ...
... brain damage and death. In the treatment of hyponatremia associated with congestive heart failure, Vaprisol is indicated only for those patients for whom ... in hospitalized patients. Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in ...
... been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection ... to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. ...
... for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known. Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA has not been formally studied in patients with CHF. Exercise ...
... and Director of Cardiac and Vascular diseases at Regenocyte Therapeutic, a company successfully treating patients with heart disease such as congestive heart failure and lung disease such as pulmonary fibrosis, COPD, and pulmonary hypertension. Adult stem cells have undergone much more research ...
... therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy. Worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cases of CHF in patients with known cardiovascular risk factors have been ...
... remodeling leading to further tissue damage over time and downstream adverse events including premature death, recurrent myocardial infarction, congestive heart failure, significant arrhythmias and acute coronary syndrome. Amorcyte's therapy aims to limit ventricular remodeling. About ...
... in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. " Phase III Study Design The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who ...
... in patients with HER-2 overexpressing breast cancer. The 3-drug combination was well tolerated. There were no cases of treatment-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity is a common and therapy-limiting adverse event of the anthracycline class of anti-cancer ...
... observed to have side effects of weight gain and abdominal obesity, which exacerbate the diabetic condition itself, and to cause edema and exacerbate congestive heart failure in certain patients. Individuals vary in their risk and there is no known method for predicting such side effects. FDA-mandated "black ...
... TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R) (rosiglitazone), which while efficacious are associated with weight gain, edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 was specifically selected for its ability to separate powerful PPAR anti-diabetic efficacy from ...
... Fatigue Syndrome and fibromyalgia as well as a general malaise of exhaustion," said Teitelbaum. Corvalen(R) is also used by physicians to treat congestive heart failure and to prepare patients for off-pump bypass surgery(1). "Bioenergy D-Ribose(TM) also has sweeping applications for healthy ...
... in patients treated with CIMZIA(R). There is no evidence that CIMZIA(R) therapy has an effect on in vivo coagulation. Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA (R) has not been formally studied in patients with CHF. ...
... seven deaths indicated above. - A third patient who was on pegloticase every 4 weeks, following a placebo dose had an SAE relating to congestive heart failure which was resolved after hospitalization. However, as previously reported, this patient died of renal failure after ...
... test (RAT) for influenza and had one or more criteria for hospitalization, namely: age greater than or equal to 60 years, chronic lung disease, congestive heart failure, diabetes mellitus, low oxygen saturation, low blood pressure, or severity of illness requiring supportive care. Of the 137 patients ...
... Gerson Lehrman Group's leading physician consultants along with executives from public and private equity biotechnology companies to discuss: -- congestive Heart Failure -- Cystic Fibrosis -- Epilepsy -- Fibromyalgia -- Lung Cancer -- Neurodegenerative Diseases -- Novel Solid Tumor Targets ...
... intended to prevent or reverse the progression of congestive heart failure in patients who have an enlarged ... heart mitral valve which contributed to congestive heart failure. During the surgery to repair the ... of the left ventricle, which is typical in congestive heart failure. As such, this new therapy has the ...
... evaluating ubiquinol's effects on late-stage congestive heart failure showed that the newly available ... "In 25 years of experience in treating congestive heart failure, we have consistently seen the best ... levels in these seven patients with end-stage congestive heart failure was associated with overall ...
Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
... this tremendous opportunity to better serve the congestive Heart Failure patient population and their ... available through physician prescription. ABOUT congestive HEART FAILURE congestive heart failure (CHF), or heart failure, is a ...Bioheart, Inc. Announces Financial Results for First Quarter 2008
... cardiac devices who are experiencing congestive heart failure. -- Bioheart initiated its ... expand our clinical body of evidence in treating congestive heart failure patients. This Phase II/III, ... myoblasts to treat patients suffering from congestive heart failure. These myoblasts, adult stem cells ...... use in treatment of acute systemic hypertension, congestive heart failure and hemorrhagic shock. The ... the next fiscal year for treatment of acute congestive heart failure; -- Advancing new Palatin ... use in treatment of acute systemic hypertension, congestive heart failure and other diseases. Palatin's ...
Genomics Likely to Replace Traditional Drug Therapies in Treating CHF
... NEW YORK, April 17 /PRNewswire/ -- The market for congestive heart failure (CHF) drug treatments was estimated ... to a new report by Kalorama Information, congestive Heart Failure: Major World Markets, Volume I: ... adequate answer. Kalorama Information's report congestive Heart Failure: Major World Markets, Volume I: ...... development for treatment of acute decompensated congestive heart failure (CHF). The Phase I trial was ... the subcutaneous route of administration. About congestive Heart Failure (CHF) Currently in the U.S., CHF ... over 1,100,000 hospitalizations for CHF in 2004. congestive heart failure has tremendous human and financial ...
... I clinical trial for MyoCell SDF-1 (Stromal Derived Factor - 1) to treat congestive heart failure. The REGEN trial will enroll 15 patients in a multicenter, ... safety and cardiovascular effects of the implantation of MyoCell SDF-1 in congestive heart failure patients post myocardial infarction(s). MyoCell SDF-1 ...
Symphony Medical Changes Name to CardioPolymers, Inc.
... biocompatible polymer implants to treat cardiac patients - specifically, congestive heart failure patients with an enlarged left ventricle." ... clinical development intended to prevent or reverse the progression of congestive heart failure in patients with dilated cardiomyopathy, a condition in ...... vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and ... (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of ...
... of doxorubicin, a dose at which 5.6% of patients are expected to develop congestive heart failure (CHF). At cumulative doses of doxorubicin in excess of ... (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of ...
... brain damage and death. In the treatment of hyponatremia associated with congestive heart failure, Vaprisol is indicated only for those patients for whom ... in hospitalized patients. Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in ...
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
... been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection ... to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. ...Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
... been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection ... to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. ...... been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection ... to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. ...
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
... (23%, 0%), superficial edema (17%, 41%), generalized edema (2%, 4%), congestive heart failure/cardiac dysfunction (2%, 0%), pericardial effusion (1%, ... gastrointestinal bleeding (4%), dyspnea (3%), sepsis (1%), diarrhea (2%), congestive heart failure (2%), and pericardial effusion (1%). Grade 3/4 elevations ...Novel gene found for dilated cardiomyopathy
... women and is most common between the ages of 20 and 60 years, although it also occurs in fetuses, newborns and children. About one in three cases of congestive heart failure is due to DCM, which also occurs in children. Dr. Towbin and his colleagues screened 208 patients, mostly children and young adults, ...... for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known. Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA has not been formally studied in patients with CHF. Exercise ...
... and Director of Cardiac and Vascular diseases at Regenocyte Therapeutic, a company successfully treating patients with heart disease such as congestive heart failure and lung disease such as pulmonary fibrosis, COPD, and pulmonary hypertension. Adult stem cells have undergone much more research ...
... therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy. Worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cases of CHF in patients with known cardiovascular risk factors have been ...
Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research
... now, every week, improving dozens and dozens of lives all over the world. He emphasized that "Patients stricken with disabling diseases such as congestive heart failure, diabetes, multiple sclerosis, spinal cord injuries, cerebral palsy, muscular dystrophy, ataxia, autism, COPD, emphysema, Crohn's, and ...... remodeling leading to further tissue damage over time and downstream adverse events including premature death, recurrent myocardial infarction, congestive heart failure, significant arrhythmias and acute coronary syndrome. Amorcyte's therapy aims to limit ventricular remodeling. About ...
... in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. " Phase III Study Design The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who ...
... in patients with HER-2 overexpressing breast cancer. The 3-drug combination was well tolerated. There were no cases of treatment-related symptomatic congestive heart failure. This is noteworthy because cardiotoxicity is a common and therapy-limiting adverse event of the anthracycline class of anti-cancer ...
... observed to have side effects of weight gain and abdominal obesity, which exacerbate the diabetic condition itself, and to cause edema and exacerbate congestive heart failure in certain patients. Individuals vary in their risk and there is no known method for predicting such side effects. FDA-mandated "black ...
Inverseon's Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
... of certain beta blockers for the treatment of asthma," commented Amie E. Franklin, PhD, of Inverseon. "A similar story played out 10 years ago in congestive heart failure where certain beta blocker drugs have become billion dollar products." "The Lancet Comment on Inverseon's human asthma study ...Victhom announces the completion of the second phase of the apnea therapy development
... disorder that happens mostly during sleep. Apnea is a co-morbidity with other physiological issues such as high blood pressure, heart attack, congestive heart failure, cardiac arrhythmia, stroke or depression. The National Sleep Foundation estimates that more than 18 million American adults suffer ...... TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R) (rosiglitazone), which while efficacious are associated with weight gain, edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 was specifically selected for its ability to separate powerful PPAR anti-diabetic efficacy from ...
VivoMetrics to Present at the 2009 Biotech Showcase
... using LifeShirt at nearly 300 leading research and academic institutions across a wide range of disease states, including sleep disordered breathing, congestive heart failure, chronic obstructive pulmonary disease and cystic fibrosis. For more information, visit www.lifeshirt.com . Forward-looking ...... Fatigue Syndrome and fibromyalgia as well as a general malaise of exhaustion," said Teitelbaum. Corvalen(R) is also used by physicians to treat congestive heart failure and to prepare patients for off-pump bypass surgery(1). "Bioenergy D-Ribose(TM) also has sweeping applications for healthy ...
... in patients treated with CIMZIA(R). There is no evidence that CIMZIA(R) therapy has an effect on in vivo coagulation. Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA (R) has not been formally studied in patients with CHF. ...
Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True
... and communications solutions for military and civilian medical use. Aiming to improve the odds for people medically at risk from dehydration or congestive heart failure, ORNL and NMT were actively engaged in improving and miniaturizing NMT's proprietary, patented ZOE(TM), an FDA-approved noninvasive ...Neurocrine Biosciences Reports Third Quarter 2008 Results
... a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression. Urocortin 2 for congestive Heart Failure (CHF) Continues Preclinical Evaluation Initiation of longer term (up to 72 hours in duration) Phase II clinical trials of urocortin 2 ...Osteoporosis Drugs Increase Risk for Heart Problems
... heart disease or hypertension," said Jennifer Miranda, MD, Jackson Memorial Hospital, Miami, FL. "If left untreated, it can lead to pulmonary edema, congestive heart failure, or the formation of a blood clot that can cause a brain embolism and stroke." In a metaanalysis, Dr. Miranda and colleagues from the ...... seven deaths indicated above. - A third patient who was on pegloticase every 4 weeks, following a placebo dose had an SAE relating to congestive heart failure which was resolved after hospitalization. However, as previously reported, this patient died of renal failure after ...
... test (RAT) for influenza and had one or more criteria for hospitalization, namely: age greater than or equal to 60 years, chronic lung disease, congestive heart failure, diabetes mellitus, low oxygen saturation, low blood pressure, or severity of illness requiring supportive care. Of the 137 patients ...
... Gerson Lehrman Group's leading physician consultants along with executives from public and private equity biotechnology companies to discuss: -- congestive Heart Failure -- Cystic Fibrosis -- Epilepsy -- Fibromyalgia -- Lung Cancer -- Neurodegenerative Diseases -- Novel Solid Tumor Targets ...
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
... consider the use of ERBITUX in combination with radiation therapy in head and neck cancer patients with a history of coronary artery disease, congestive heart failure or arrhythmias in light of these risks - Closely monitor serum electrolytes including serum magnesium, potassium, and calcium during ...Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
... complications such as pneumonia. In addition, influenza exacerbates the symptoms of chronic health conditions such as diabetes, asthma and congestive heart failure. The most severe disease occurs in infants and young children and adults older than 65 years of age. The CDC reports that 15 to 60 ...Other ContentszinczinczinczinczinczincabsorptionabsorptionabsorptionabsorptionabsorptionabsorptionabsorptionabsorptionacrosomeacrosomeactivationactivationactivationactivationactivationactivationactivationactivationactivationsitesitesitesitesitesitesitesitesitesiteOther TagsNitricLegalLegalPrematurePrematureInvasionPercutaneousDealingSlowing
(Date:11/9/2009)...ber 09, 2009 / b3c newswire / - Today, TNO, a D...ave, an American organization for contract researc...e signed a letter of intent with regard to TNOs dy...letter of intent proposes a collaboration in which...ercialization in North America. The TIM systems wi...
(Date:11/9/2009)...009 A nutritionist whose research was instrumenta...omen, Infants and Children (WIC) food subsidy will...r outstanding achievement in the field of maternal... , a professor in the Department of Community Heal...ngeles School of Public Health, will receive the a...
(Date:11/8/2009)...D FOR ADULTS WITH INTELLECTUAL DISABILITIES: AN OP...ersity study involving adults with intellectual di...ersonal health knowledge after taking a semi-weekl...ternationally accepted term for mental retardation...inactivity and preventable chronic diseases compar...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 12864 1Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 12864 2Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 12864 3Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine 12864 4Chromosomal problems affect nearly all human embryos 9081 1Chromosomal problems affect nearly all human embryos 9081 2Chromosomal problems affect nearly all human embryos 9081 3Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 1Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 2Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 3(Date:11/9/2009)...v. 9 Sutter Health, a family of do...are service providers, is donating $255,000 to foo...ocal food banks will share the quarter-million-dol...tables of thousands of families across the north s...partnering with and supporting charitable programs...
(Date:11/9/2009)...s with drugs that inhibit estrogen, , ,... to treat breast cancer and osteoporosis eliminate...y. , The drugs also cleared precancerous growth...t of cancer in mice with precancerous lesions. ,...t cancer/osteoporosis drug raloxifene were given t...
(Date:11/9/2009)... both eye conditions are age-related, researchers ...-- Cataract surgery doesn,t appear to speed the pr...), according to a new study that challenges the be...s the other. , "Because both conditions are str...also have AMD," wrote Li Ming Dong, of Stony Brook...
(Date:11/9/2009)...9 /PRNewswire-FirstCall/ - Hard To Treat Diseases ...hat Novartis, a US$41 billion international health...1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmac... Switzerland will begin a five-year, $1 billion Ch...matically increase its investment in its China R&a...
(Date:11/9/2009)...sive Cancer Network (NCCN) has posted a draft whit...radigm for near-term comparative effectiveness cli...cument introduces the NCCN Comparative Therapeutic...ompares the risk-versus-benefit of different treat...tice Guidelines in Oncology(TM). The paper will be...
Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4[0] Sutter Health Donates $255,000 to Help the Hungry This Holiday Season[0] Breast Cancer Drugs May Fight Cervical Cancer, Too[0] Cataract Surgery Doesn't Worsen Macular Degeneration: Study[2] Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million[0] NCCN Posts Comparative Effectiveness White Paper for Public Comment
NitricMaggotsLegalTraumasPrematureInvasionEgyptiansDiminishingWartsBaumannToxoplasmosisPercutaneousDealingSlowing
Other Tagsadministration 2administration 3administration 4administration 5administration 6administration 7administration 8administration 9administration 10primates 2primates 3degenerative 2degenerative 3degenerative 4degenerative 5degenerative 6degenerative 7degenerative 8happen 2happen 3happen 4happen 5happen 6happen 7happen 8happen 9happen 10being 2being 3being 4being 5being 6being 7being 8being 9being 10countries 2countries 3countries 4countries 5countries 6countries 7countries 8countries 9countries 10emergence 2emergence 3emergence 4message 2message 3message 4message 5tune 2channels 2channels 3channels 4channels 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |